| Acute Leukemia |
1 |
1 |
| Stem Cell Research and Therapy |
0 |
0.98 |
| Transplantation |
0 |
0.97 |
| Biologic Therapy |
0 |
0.56 |
| Anaphylaxis |
0 |
0.41 |
| Graft Versus Host Disease and Transplant Complications |
0 |
0.41 |
| Chemotherapy |
0 |
0.33 |
| Immunotherapy |
0 |
0.26 |
| Residual Disease |
0 |
0.2 |
| Child |
0 |
0.13 |
| Genetics |
0 |
0.13 |
| Hand |
0 |
0.13 |
| Hematology |
0 |
0.13 |
| Plantar |
0 |
0.13 |
| Remission |
0 |
0.13 |
| Acute Graft Versus Host Disease |
0 |
0.11 |
| Leukemia |
0 |
0.1 |
| Acute Lymphoblastic Leukemia |
0 |
0.99 |
| Bone Marrow |
0 |
0.09 |
| Graft Versus Host Disease |
0 |
0.09 |
| Genomic Medicine |
0 |
0.08 |
| Blood |
0 |
0.07 |
| Bone |
0 |
0.07 |
| California |
0 |
0.07 |
| CAR-T |
0 |
0.07 |
| France |
0 |
0.07 |
| Graft |
0 |
0.07 |
| Insurance |
0 |
0.07 |
| Minnesota |
0 |
0.07 |
| Refractory |
0 |
0.07 |